Monoclonal antibody pharmaceutical wastewater treatment method

Abstract

The invention belongs to the technical field of pharmaceutical wastewater treatment, and particularly relates to a monoclonal antibody pharmaceutical wastewater treatment method. The method comprises:A, wastewater pretreatment: removing SS pollutants in wastewater, reducing COD and BOD pollutants, and removing precipitation impurities; B, anaerobic hydrolytic acidification: carrying out hydrolytic acidification reaction on the wastewater without the precipitate pollutants by adopting bacterial enzymes under an anaerobic condition to remove residual COD and BOD pollutants; C, aerobic decomposition: removing pollutants in the wastewater subjected to hydrolytic acidification under the action of aeration and microorganisms; D, MBR filtration treatment; and E, disinfection treatment. By adopting a wastewater treatment process of 'pretreatment+secondary biochemistry+MBR filtration', the MBR tank is arranged at the tail end to further remove organic matters and biological residues in the wastewater, and compared with an SBR tank, the MBR tank operates continuously, so that the concentration of sludge obtained by treating the wastewater is higher, and the amount of discharged sludge is relatively small.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical wastewater treatment, and in particular relates to a treatment method for monoclonal antibody pharmaceutical wastewater. Background technique [0002] The wastewater produced by the pharmaceutical industry is one of the most difficult-to-treat high-concentration organic wastewater at home and abroad, and it is also one of the most polluted and most difficult-to-treat industrial wastewater in China. [0003] The ingredients for the preparation of monoclonal antibody drugs mainly include tricyclic urea compounds, pyridophthaloin ketone compounds, dihydrodiaza*carbazolones, 5-amino-4-carbamoyl-pyrazole compounds, etc. Therefore, the wastewater produced by monoclonal antibody drugs has a complex composition, many types of organic pollutants, a low ratio of BOD to COD and large fluctuations, a high concentration of SS, and large fluctuations in water volume. At present, the commonly used method...

AI Technical Summary

Problems solved by technology

[0003] The ingredients for the preparation of monoclonal antibody drugs mainly include tricyclic urea compounds, pyridophthaloin ketone compounds, dihydrodiaza*carbazolones, 5-amino-4-carbamoyl-pyrazole compounds, etc. Therefore, the wastewater produced by monoclonal antibody drugs has a complex composition, many types of organic pollutants, a low ratio of BOD to COD and large fluctuations, a high concentration of SS, and large fluctuations in water volume.

At present, the commonly used methods for treating pharmaceutical wastewater include physical and chemical methods, chemical methods, biochemical methods, and a combination of multiple processes, but they face problems such as large fluctuations in water quality, poor biochemical properties, and high operating costs.

[0004] Patent CN103739138A discloses a treatment process for wastewater from the production of Chinese medicinal pieces, which discloses the use of USAB reaction towers and SBR pools to treat wastewater. However, the USAB reaction tower will have high energy consumption of the reflux pump, which is relatively prone to the phenomenon of running sludge. The SBR pool For intermittent operation, there is instability in wastewater treatment

Images